Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label blinded-endpoint trial of tenecteplase for acute pulmonary embolism
CTR20233259Phase 2Active
- Sponsor
- Shanghai Fenghua Tianlitong Biomedical
- Start
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of tenecteplase in pulmonary embolism (PE), sponsored by Shanghai Fenghua Tianlitong Biomedical. Started Oct 2023; status: active.
02
Drugs
tenecteplase
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on CTR20233259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233259.